tiprankstipranks
Trending News
More News >
Xspray Pharma AB (SE:XSPRAY)
:XSPRAY

Xspray Pharma AB (XSPRAY) AI Stock Analysis

Compare
1 Followers

Top Page

SE

Xspray Pharma AB

(Berlin:XSPRAY)

Rating:47Neutral
Price Target:
Xspray Pharma AB's stock score reflects significant financial challenges, particularly the lack of revenue and increasing debt levels, which weigh heavily on the overall assessment. While technical indicators show some positive momentum, they are not strong enough to offset the financial concerns. The stock's valuation, characterized by a negative P/E ratio, underscores the company's unprofitability. To improve the stock's attractiveness, achieving revenue generation and financial sustainability will be critical.

Xspray Pharma AB (XSPRAY) vs. iShares MSCI Sweden ETF (EWD)

Xspray Pharma AB Business Overview & Revenue Model

Company DescriptionXspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo for the treatment of chronic myeloid leukemia; HyNap-Sora for the treatment of renal cancer and liver cancer, as well as several forms of thyroid cancer; and HyNap-Dasa for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is based in Solna, Sweden.
How the Company Makes MoneyXspray Pharma makes money by developing and commercializing improved versions of existing cancer drugs. The company's revenue model is based on licensing agreements and collaborations with larger pharmaceutical companies that have the resources and distribution networks to market the drugs. By using its HyNap technology, Xspray creates formulations that offer competitive advantages over original drugs, such as enhanced bioavailability and reduced side effects, making them attractive for licensing. Xspray typically earns upfront payments, milestone payments, and royalties from these partnerships. Additionally, the company may also generate revenue through direct sales if it chooses to commercialize certain products independently.

Xspray Pharma AB Financial Statement Overview

Summary
Xspray Pharma AB faces significant financial challenges typical of early-stage biotechnology firms, such as lack of revenue generation and profitability. The strong equity position and liquidity provide some stability, but the reliance on external funding and increasing debt levels pose future risks. A focus on achieving operational efficiency and revenue generation is critical for improving financial health.
Income Statement
20
Very Negative
Xspray Pharma AB has consistently reported zero revenue over the years, indicating a lack of commercial operations or product sales. The company has been experiencing increasing losses, with net income significantly negative, which reflects ongoing financial challenges in achieving profitability. The EBIT and EBITDA margins are negative, further emphasizing the lack of operational efficiency and profitability.
Balance Sheet
45
Neutral
The balance sheet shows a strong equity position with a high equity ratio, indicating a solid capital base. However, the company has been increasing its debt levels, which is reflected in a rising debt-to-equity ratio. Despite the challenges, a substantial portion of the assets consists of cash and short-term investments, providing some liquidity cushion.
Cash Flow
30
Negative
Xspray Pharma AB has been generating negative operating and free cash flows, indicating cash burn from operations and investments. The company relies heavily on financing activities for cash inflows, which could be a concern if external funding becomes less accessible. No positive growth in free cash flow has been observed, signaling potential sustainability issues.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
930.00K0.000.000.000.000.00
Gross Profit
930.00K0.00-9.19M-9.53M-8.87M-1.41M
EBIT
-257.84M-287.04M-181.73M-133.07M-97.95M-53.46M
EBITDA
-247.26M-277.76M-169.81M-122.13M-87.82M-50.99M
Net Income Common Stockholders
-260.07M-285.52M-179.67M-130.27M-96.70M-52.30M
Balance SheetCash, Cash Equivalents and Short-Term Investments
125.72M208.24M166.30M120.17M271.88M325.60M
Total Assets
737.71M796.34M765.26M585.43M622.90M605.30M
Total Debt
126.96M128.22M36.81M2.13M3.23M4.86M
Net Debt
1.23M-80.02M-129.50M-118.04M-268.65M-320.74M
Total Liabilities
157.25M173.25M71.85M29.41M31.15M22.72M
Stockholders Equity
580.46M623.10M693.41M556.02M591.75M582.59M
Cash FlowFree Cash Flow
-285.08M-264.51M-257.38M-238.47M-147.57M-145.00M
Operating Cash Flow
-233.39M-222.37M-203.28M-110.18M-51.61M-47.79M
Investing Cash Flow
-51.69M-42.14M-65.88M-135.34M-105.82M-96.83M
Financing Cash Flow
306.54M306.11M315.59M93.81M103.71M260.35M

Xspray Pharma AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price32.00
Price Trends
50DMA
32.02
Positive
100DMA
31.85
Positive
200DMA
39.36
Negative
Market Momentum
MACD
-0.12
Negative
RSI
55.69
Neutral
STOCH
70.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XSPRAY, the sentiment is Positive. The current price of 32 is above the 20-day moving average (MA) of 31.51, below the 50-day MA of 32.02, and below the 200-day MA of 39.36, indicating a neutral trend. The MACD of -0.12 indicates Negative momentum. The RSI at 55.69 is Neutral, neither overbought nor oversold. The STOCH value of 70.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:XSPRAY.

Xspray Pharma AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
kr1.28B4.71152.78%1533.99%
54
Neutral
€413.69M-47.73%45.52%93.35%
54
Neutral
$5.38B3.40-45.06%3.28%16.75%-0.02%
48
Neutral
kr825.31M-48.22%67.70%
47
Neutral
kr1.19B-42.24%-19.44%
40
Neutral
kr368.27M-194.31%1643.36%50.36%
31
Underperform
kr255.08M-167.55%46.67%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:XSPRAY
Xspray Pharma AB
33.00
-51.88
-61.12%
SE:CANTA
Cantargia AB
1.12
-3.48
-75.74%
SE:IRLAB.A
IRLAB Therapeutics AB Class A
7.09
-6.91
-49.36%
SE:SANION
Saniona AB
9.11
5.63
161.41%
SE:XBRANE
Xbrane Biopharma AB
0.26
-0.04
-13.77%
SE:SYNACT
SynAct Pharma AB
17.00
10.00
143.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.